Yang J, She Q, Yang Y, Tao H, Li J. DNMT1 controls LncRNA H19/ERK signal pathway in hepatic stellate cell activation and fibrosis. Toxicol Lett. 2018;295:325-334 pubmed publisher
..These data connect HSCs activation with a DNMT1-LncRNA H19 epigenetic pathway that is important for liver fibrosis. ..
Yang J, Tao H, Deng Z, Lu C, Li J. Non-coding RNA-mediated epigenetic regulation of liver fibrosis. Metabolism. 2015;64:1386-94 pubmed publisher
..These epigenetic mechanisms form powerful ncRNAs surveillance systems that may represent new targets for liver fibrosis therapeutic intervention. ..
Tao H, Yang J, Hu W, Shi K, Deng Z, Li J. MeCP2 regulation of cardiac fibroblast proliferation and fibrosis by down-regulation of DUSP5. Int J Biol Macromol. 2016;82:68-75 pubmed publisher
..Taken together, these results indicated that MeCP2 acts as a key regulator of pathological cardiac fibrosis, promotes cardiac fibroblasts proliferation and fibrosis by down-regulation of DUSP5. ..
Tao H, Yang J, Shi K, Li J. Epigenetic factors MeCP2 and HDAC6 control Î±-tubulin acetylation in cardiac fibroblast proliferation and fibrosis. Inflamm Res. 2016;65:415-26 pubmed publisher
..This study indicated that MeCP2 could be a potentially new therapeutic option for cardiac fibrosis. ..
Yang J, Tao H, Liu L, Hu W, Deng Z, Li J. miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway. Inflamm Res. 2017;66:341-352 pubmed publisher
..Finally, HSC transfected with SIRT1-siRNA increased the levels of Notch1 protein and mRNA expression. Our study demonstrated that miR-200a regulates SIRT1/Notch1 expression during HSC activation and fibrosis. ..
Yang J, Liu L, Tao H, Hu W, Shi P, Deng Z, et al
. MeCP2 silencing of LncRNA H19 controls hepatic stellate cell proliferation by targeting IGF1R. Toxicology. 2016;359-360:39-46 pubmed publisher
..Taken together, these results demonstrated that MeCP2 silencing of H19 can alter the IGF1R overexpression, thus contributing to HSCs proliferation. These data could suggest the development of combination therapies that target the MeCP2. ..